Business
Portfolio Update
Portfolio Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0336C Sareum Holdings PLC 13 June 2019 \n\n\n\n\n(AIM: SAR)\n\n\n13 June 2019\n\n\n\n \nThis announcement contains inside information for the purposes of Article 7 of regulation 596/2014\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nPortfolio Update\n \nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, follows the Company's recent announcements on SRA737 with an update on other developments within its active preclinical portfolio.\n \nThe Company's active development portfolio comprises candidates being developed internally (SDC-1801 and SDC-1802) and a partnered programme (SRA737) that is out-licensed to Sierra Oncology.\n \nThese potent and selective small molecules target important mechanisms in cancer and autoimmune diseases and provide potentially high-value opportunities to develop new therapies for patients. \n \nSelective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer\n \nSareum's internal programmes focus on distinct dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first-in-human clinical trials in 2020.\n \nBoth Sareum programmes have progressed well since candidate nomination in September 2018, building on the compelling efficacy seen in disease models, the potential for once-daily oral dosing and good early safety profiles. Data arising from some of this work are being prepared for submission to a peer-reviewed publication and a conference presentation.\n \nSareum's recent activities have focused on toxicology studies designed to gain insight to the maximum-tolerated doses (MTD) of SDC-1801 and SDC-1802 in rodents. SDC-1801 is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; an MTD has yet to be reached. \n \nMultiple dose-finding studies are now ongoing to identify doses to use in specific toxicology studies, which are intended to form part of the applications for initial human trials. Additional research to refine the clinical plans, including prioritisation of potential target indications, is continuing.\n&nbs...